Alzheimer's disease is the most prevalent form of dementia. No effective treatments to stop the onset or the progression of the disease are currently available. The most accepted theory establishes amyloid-beta aggregates as the cause of the onset and the development of the disease. Many efforts have been made in recent years to target amyloid-beta but no effective treatments have passed the clinical trials. Here, a human naïve phage library based on blood samples from six healthy people has been used to produce a single-domain antibody that recognizes specifically the oligomers of amyloid-beta 42. The Western blot and ELISA results show that this antibody binds specifically to human amyloid-beta 42 tetramer and nonamer oligomers but not to monomers or other oligomers. In this study, the researchers produce a new human phage display library that allows them to find a single domain antibody, which facilitates organ penetration, to target specifically amyloid-beta oligomers, which has the potential to be further developed as immunotherapy against Alzheimer's disease.
Construction of human Fab library and screening of a single-domain antibody of amyloid-beta 42 oligomers
The IE from MS no longer understands current scripting languages, the latest main version (version 11) is from 2013 and has not been further developed since 2015.
Our recommendation: Use only the latest versions of modern browsers, for example Google Chrome, Mozilla Firefox or Microsofrt Edge, because only this guarantees you sufficient protection against infections and the correct display of websites!